ABSTRACT

Community-acquired pneumonia (CAP) is a frequent and potentially serious infection associated with high morbidity and mortality, particularly in adults and vulnerable groups, despite research and information and the development of new antimicrobial agents. This document represents the effort of a group of experts to disseminate knowledge about the prevention of CAP through pneumococcal conjugate vaccination in adults, especially in patients with comorbidities such as heart, lung and rheumatic diseases, diabetes mellitus, cancer and human immunodeficiency virus infection (HIV), among others. The objective is to provide recommendations on pneumococcal conjugate vaccination to physicians who treat adult patients with comorbidities such as those mentioned above.

KEYWORDS

Adult immunization, immunocompromised adults, community-acquired pneumonia, PCV13, community-acquired pneumonia prevention, neumococcal conjugate vaccine, vaccines.

REFERENCES

1. Prevención, diagnóstico y tratamiento de la neumonía adquirida en la comunidad. Guía de Evidencias y Recomendaciones. Guía de Práctica Clínica. México, CENETEC; 2017. Disponible en: http://www.cenetec.salud.gob.mx/contenidos/gpc/catalogoMaestroGPC.html#

2. Dang TT, Eurich DT, Weir DL, Marrie TJ, Majumdar SR. Rates and risk factors for recurrent pneumonia in patients hospitalized with community- acquired pneumonia: population-based prospective cohort study with 5 years of follow-up. Clin Infectious Dis 2014;59(1):74-80.

3. Rivero-Calle I, Pardo-Seco J, Aldaz P, Vargas DA, Mascaros E, Redondo E, et al. Incidence and risk factor prevalence of community-acquired pneumonia in adults in primary care in Spain (NEUMO-ES-RISK project). BMC Infectious Dis 2016;16:645.

4. Chalmers JD, Campling J, Dicker A, Woodhead M, Madhava H. A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults. BMC Pulmonary Med 2016;16:77.

5. Mandell LA, Wunderink RG. Neumonía (capítulo 153). En: Kasper DL, Hauser SL, Jameson JL, et al. editores. Harrison Principios de Medicina Interna. Vol 2. 19a ed. México: McGraw-Hill; 2015. pp. 803-806.

6. Escobar-Rojas A, Castillo-Pedroza J, Cruz-Hervert P, Báez-Saldaña R. Tendencia de morbilidad y mortalidad por neumonía en adultos mexicanos (1984-2010). Neumol Cir Torax 2015;74(1):4-12.

7. Tasa de morbilidad de los principales casos nuevos de enfermedades, 2000 a 2013. consultado en: http://www3.inegi.org.mx/sistemas/sisept/default.aspx?t=msal06&s=est&c=22462

8. Báez-Saldaña R, Gómez-Zamora C, López-Elizondo C, Molina-Corona H, Santillán-Martínez A, Sánchez-Hernández J, et al. Neumonía adquirida en la comunidad. Revisión y actualización con una perspectiva orientada a la calidad de la atención médica. Neumol Cir Torax 2013;72(1):6-43.

9. Trejo-Valdivia B, Mendoza-Alvarado LR, Palma-Coca O, Hernández-Ávila M, Téllez-Rojo Solís MM, et al. Encuesta Nacional de Cobertura de Vacunación (influenza, neumococo y tétanos) en Adultos Mayores de 60 años en México. Salud Publica Mex 2012;54:39-46.

10. Julio V, Vacarezza M, Álvarez C, Sosa A. Niveles de atención, de prevención y atención primaria de la salud. Arch Med Interna 2011;33(1):11-14.

11. Evolución de las vacunas contra Streptococcus pneumoniae. Consultado en: https://www.historyofvaccines.org/es/contenido/articulos/enfermedad-neumoc%C3%B3cica

12. Prevention of Pneumococcal Disease. Recommendations of the advisory committee on immunization practices (ACIP). MMWR 1997;46:1-24.

13. Introduction of Pneumococcal Vaccine PCV10. A handbook for district and health facility staff. WHO 2013. Consultado en: https://apps.who.int/iris/bitstream/handle/10665/90378/WHO_IVB_13.09_eng.pdf;jsessionid=C7C92B23CA6AF4251A67DC1B7C069FDE?sequence=1

14. González-Romo F, Picazo JJ, García-Rojas A, Labrador-Horrillo M, Barrios V, Magro MC, et al. Consenso sobre la vacunación anti-neumocócica en el adulto por riesgo de edad y patología de base. Actualización 2017. Rev Esp Quimioter 2017;30(2):142-168.

15. Definición conjugada y polisacárida. Consultado en: https://www.cdc.gov/pneumococcal/vaccination-sp.html

16. Información para prescribir amplia Prevenar® 13V.

17. Pletz MW, Maus U, Krug N, Welte T, Lode H. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrobial Agents. 2008;32:199-206.

18. Información para prescribir Pneumo23. Consultada en: http://www.medicamentosplm.com/Home/productos/pneumo_23_solucion_inyectable/161/101/9308/162

19. 2018 Recommended immunizations for adults by age and by Health condition CDC. Consultada en: https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-schedule-easy-read.pdf

20. Suaya JA, Jiang Q, Scott DA, Gruber WC, Webber C, Schmoele-Thoma B, et al. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults. Vaccine 2018;36:1477-1483.

21. Tanriöver MD, Akar S, Türkcapar N, Karadag O, Ertenli I, Kiraz S. Vaccination recommendations for adult patients with rheumatic diseases. Eur J Rheumatol 2016;3:29-35.

22. Gutiérrez-Robledo LM, Caro-López E, Guerrero-Almeida ML, Dehesa-Violante M, Rodríguez-Noriega E, García-Lara JM, et al. 1o Consenso Mexicano de Vacunación en el Adulto. Gac Med Mex 2017;153:5-70.

23. Steel HC, Cockeran R, Anderson R, Feldman C. Overview of community-acquired pneumonia and the role of inflammatory mechanisms in the immunopathogenesis of severe pneumococcal disease. Mediators of Inflammation 2013; http://dx.doi.org/10.1155/2013/490346

24. Bonten MJM, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015;372:1114-1125.

25. Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Consultado en: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6434a4.htm?s_cid=mm6434a4_w

26. Declaratoria emergencia epidemiológica por diabetes mellitus. Consultada en: https://www.gob.mx/salud/prensa/emite-la-secretaria-de-salud-emergencia-epidemiologica-por-diabetes-mellitus-y-obesidad

27. Kesavadeb J, Misra A, Kumar-Das A, Saboo B, Basu D, Thomas M, et al. Suggested use of vaccines in diabetes. Indian J Endocrinol Metab 2012;16(6):886-893.

28. Klekotka RB, Mizgala E, Krol W. The etiology of lower respiratory tract infections in people with diabetes. Pneumonol Alergol Pol 2015;83:401-408.

29. Van Deursen AMM, van Houten MA, Webber C, Patton M, Scott DA, Patterson S, et al. Immunogenicity of the 13-valent pneumococcal conjugate vaccine in older adults with and without comorbidities in the community-adquired pneumonia immunization trial in adults (CAPiTA). Clin Infectious Dis 2017;65(5):787-795.

30. 2017 ADA Guidelines: Comorbidities and Diabetes: Immunization. Consultado en: https://www.gertitashkomd.com/blog/2017/5/12/2017-ada-guidelines-comorbidities-and-diabetes

31. Recommended Immunization Schedule for Adults Aged 19 years or Older, United States, 2018. Consultado en: https://www.cdc.gov/vaccines/schedules/hcp/imz/adult-conditions.html

32. Martins WA, Domingues-Ribeiro M, Brandáo de Oliveira L, da Silva-Nogueira de Barros L, da Silva Moreira Jorge C, et al. Vacunación contra Influenza y Neumococo en la Insuficiencia Cardíaca – Una recomendación poco aplicada. Arq Bras Cardiol 2011;96(3):240-245.

33. Bornheimer R, Shea KM, Sato R, Weycker D, Pelton SI. Risk of exacerbation following pneumonia in adults with heart failure or chronic obstructive pulmonary disease. PLoS ONE 2017;12(10):e0184877.

34. Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang CCH, et al. Association between hospitalization for pneunomia and subsequent risk of cardiovascular disease. JAMA 2015;313(3):264-274.

35. Elkayam O, Paran D, Caspi D, Litinsky I, Yaron M, Charboneau D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infectious Dis 2002;34:147-153.

36. Brenol CV, Azevedo VF, Bonvehi PE, Coral-Alvarado PX, Granados J, Muñoz-Louis R, et al. Vaccination recommendations for adults with autoimmune inflammatory rheumatic diseases in Latin America. J Clin Rheumatol. 2018;24(3):138-147.

37. Van Assen S, Elkayam O, Agmon-Levin N, Cervera R, Doran MF, Dougados M, et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: A systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmunity Rev 2011;10:341-352.

38. Meroni PL, Zavaglia D, Girmenia C. Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs. Clin Exp Rheumatol 2018;36:317-328.

39. Hesselstrand R, Nagel J, Saxne T, Geborek P, Skattum L, Kapetanovic MC. Immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosis. Rheumatol 2018;57(4):625-630.

40. Van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. EULAR Recommendations for Vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011;70:414-422.

41. Kumar S, Rath P, Malaviya AN. A practical guide to adult vaccination for patients with autoimmune inflammatory rheumatic diseases in India. Indian J Rheumatol 2017;12:160-168.

42. Westra J, Rondaan C, van Assen S, Bijl M. Vaccination of patients with autoimmune inflammatory rheumatic diseases. Nat Rev Rheumatol 2015;11(3):135-145.

43. Wong A, Marrie TJ, Garg S, Kellner JD, Tyrrell GJ, et al. Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies. Epidemiol Infect 2010;138:1804-1810.

44. Guía de práctica clínica basada en la evidencia sobre la eficacia de la vacunación contra Streptococcus pneumoniae y virus influenza en pacientes oncológicos. 2007. Consultada en: http://www.cancer.gov.co/files/libros/archivos/f7ec662fccc31d9f9446a9c62a159324_Guia%20N4%20%20pacientes%20vacunas%20con%20cancer.pdf

45. Berglund A, Willen L, Grödeberg L, Skattum L, Hagberg H, Pauksens K. The response to vaccination against influenza A (H1N1) 2009, seasonal influenza and Streptococcus pneumonia in adult outpatients with ongoing treatment for cancer with and without rituximab. Acta Oncologica 2014;53:1210-1220.

46. Zarco-Márquez S, Volkow-Fernández P, Velázquez-Acosta C, Echániz-Áviles G, Carnalla-Barajas MN, Soto-Noguerón A, et al. Invasive and complicated pneumococcal infection in patients with cancer. Rev Inves Clin 2016;68:221-228.

47. Toleman MS, Herbert K, McCarthy N, Church DN. Vaccination of chemotherapy patients-effect of guideline implementation. Support Care Cancer 2016;24(5):2317-2321.

48. Rodrigo C. Intervalos de administración de vacunas entre sí y entre vacunas y otros productos inmunobiológicos. Intercambio de preparados vacunales. En: Arístegui J (Ed.). Vacunaciones en el niño. De la teoría a la práctica. Bilbao: Ciclo Editorial; 2004. pp. 93-97.

49. Ullrich D, Ullrich K, Mussler S, Thum-Oltmer S. Vaccination during concurrent subcutaneous immunotherapy: safety of simultaneous application. Eur Ann Allergy Immunol 2015;47:10-14.

50. Chicaíza-Becerra LA, García-Molina M, Ballesteros M, Gamboa O, Díaz J, Vega R, et al. Impacto económico de la vacuna contra el neumococo en pacientes oncológicos. Rev Salud Pública 2007;9(3):342-352.

51. Manual de Vacunación CONAVA 2017. Consultado en: http://bit.ly/2n1vF8S

52. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. Clin Infectious Dis 2014;58(3):e44-100.

53. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/365/figure--immunization https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/365/figure--immunization

54. Informe sobre la salud de los mexicanos 2015. Consultado en: https://www.gob.mx/cms/uploads/attachment/file/64176/INFORME_LA_SALUD_DE_LOS_MEXICANOS_2015_S.pdf

55. Informe sobre la salud de los mexicanos 2016. Consultado en: https://www.gob.mx/salud/documentos/informe-sobre-la-salud-de-los-mexicanos-2016-116713?state=published

56. Tinoco JC, Juergens C, Ruiz-Palacios GM, Vázquez-Narváez J, Enkerlin-Pauwells HL, Sundaraiyer V, et al. Open-label trial of immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 50 years of age in Mexico. Clin Vaccine Immunol 2015;22(2):185-192.

57. Solanki BB, Juergens C, Chopada MB, Supe P, Sundariyer V, Le Dren-Narayanin N, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial. Human Vaccines & Immunotherapeutics 2017;13(9):2065-2071.